JVI Try JB online
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otten, G.
Right arrow Articles by Ulmer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otten, G.
Right arrow Articles by Ulmer, J.
Journal of Virology, May 2003, p. 6087-6092, Vol. 77, No. 10
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.10.6087-6092.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

Gillis Otten,* Mary Schaefer, Catherine Greer, Maria Calderon-Cacia, Doris Coit, Jina Kazzaz, Angelica Medina-Selby, Mark Selby,{dagger} Manmohan Singh, Mildred Ugozzoli, Jan zur Megede, Susan W. Barnett, Derek O'Hagan, John Donnelly, and Jeffrey Ulmer

Vaccines Research, Chiron Corporation, Emeryville, California 94608

Received 26 June 2002/ Accepted 29 January 2003

Several vaccine technologies were evaluated for their abilities to induce anti-human immunodeficiency virus Gag immune responses in rhesus macaques. While no vaccine alone was able to induce broad and strong immune responses, these were achieved by priming with Gag DNA and boosting with Gag protein adsorbed to polylactide coglycolide microparticles. This regimen elicited strong antibodies, helper T cells, and cytotoxic T lymphocytes and thus holds promise as an effective vaccination scheme.


* Corresponding author. Mailing address: Vaccines Research, Chiron Corporation, 4560 Horton St., Mail Stop 4.3, Emeryville, CA 94608. Phone: (510) 923-2965. Fax: (510) 923-2586. E-mail: Gillis_Otten{at}chiron.com.

{dagger} Present address: Medarex, Milpitas, CA 95035.


Journal of Virology, May 2003, p. 6087-6092, Vol. 77, No. 10
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.10.6087-6092.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.